NEXI-002

Overview

NEXI-002 is an autologous T cell therapy that consists of T cell populations directed against multiple tumor-relevant antigen targets: WT1, CD138, CS1 and NY-ESO-1.

SparkCures ID 350
Developed By NexImmune
Generic Name NEXI-002
Treatment Classifications
  • Adoptive Cellular Therapy
Treatment Targets

Clinical Trials

Resources